Jérôme Galon
Research Director
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (15)
Kaplan Meier estimates of progression-free survival in the pMMR population (optimized cut-point), according to IO status (a) and to both IO status and treatment arm (b).Legend: HR: hazard ratio, NR: not reached. Control arm indicates FOLFOXIRI plus bevacizumab. Atezo arm indicates FOLFOXIRI plus bevacizumab and atezolizumab.
Year:
2025
Kaplan Meier estimates of progression-free survival in the overall population (optimized cut-point), according to IO status (a) and to both IO status and treatment arm (b).Legend: HR: hazard ratio, NR: not reached. Control arm indicates FOLFOXIRI plus bevacizumab. Atezo arm indicates FOLFOXIRI plus bevacizumab and atezolizumab.
Year:
2025
The genetic reprogramming of T cells with chimeric antigen receptors (CAR) specifically targeting CD19 in B-cell malignancies or B-cell maturation antigen for plasma cell tumors has achieved remarkable success. CAR T-cell therapy represents a revolutionary strategy in personalized cancer care, leveraging the immune system's precision to target cancer cells with unprecedented efficacy. However, challenges persist, with resistance and relapse occurring in hematologic malignancies. Understanding the intricate mechanisms governing response and resistance is crucial, emphasizing factors such as pharmacokinetics, product attributes, and tumor biology. This review focuses on biomarkers associated with CAR T-cell therapy in mature B-cell non-Hodgkin lymphoma malignancies, underscoring the importance of preexisting tumor immune contexture. Previous findings highlight strong correlation between early peak levels of CAR-T cells after treatment initiation and treatment response. Maintaining an optimal CAR T-cell–to–tumor burden ratio is essential for sustained responses. Systemic and tumor immune contexture affects therapy outcomes, revealing preexisting immunity's role in CAR T-cell efficacy. The mechanistic impact of CAR-T cells was investigated using pre- and posttreatment biopsies, revealing specific markers associated with treatment response in refractory large B-cell lymphoma, across patients receiving CAR T-cell therapy in the second- and third-line settings, supporting precision medicine in developing next-generation cell therapies for hematologic malignancies. The evolution of the tumor microenvironment with therapy lines was also demonstrated, supporting earlier intervention with CAR T-cell therapy. Ongoing translational efforts, including single-cell omics analysis, aim to uncover additional factors that affect outcomes to develop more potent treatments.
Year:
2025
Schematic representation of CAR T-cell structure and mechanism of action. Designed CAR receptors comprising a receptor domain, CD28 co-stimulatory domain, and CD3ζ activation domain bind to CD19 antigens on the surface of lymphoma cells. This binding event initiates T-cell activation, triggering the release of granzymes and cytokines. Preexisting immune cells, including T cells and myeloid cells, support CAR-T cells through the production granzymes, cytokines, and chemokines. This process induces the targeted death of B-cell lymphoma. CCL2, chemokine ligand 2; CCL5, chemokine ligand 5; CXCL9, C-X-C motif chemokine ligand 9; GNLY, granulysin; GZMA, granzyme A; GZMB, granzyme B; ScFv, single-chain variable fragment.
Year:
2025
Background Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, providing durable and even curative responses. However, most patients do not respond and current biomarkers (eg, programmed death ligand (PD-L1), mismatch repair deficiency (dMMR)/high microsatellite instability (MSI) and tumor mutational burden) lack predictive accuracy. Ex vivo profiling of patient-derived tumor fragments shows promise as a predictive biomarker but relies on substantial surgical tissue to mitigate intra-specimen heterogeneity. Innovations are needed that address these challenges, particularly where limited tissue is available in core needle biopsies (CNBs). Methods Live tumor fragments (LTFs) were generated from 59 human tumor resections and 31 CNBs from patients enrolled in observational clinical trials (ClinicalTrials.gov identifiers: NCT05478538 , NCT05520099 , NCT06349642 ) to assess cytokine induction following ICI treatment. LTFs were encapsulated in hydrogel and cultured ex vivo for up to 72 hours. A sequential treatment strategy that applies control and treatment within the same well was used with response to ICI or αCD3/αCD28 assessed using a multiplex secretome assay. Viability was assessed using established metabolic assays and dynamic optical coherence microscopy. Results LTFs maintained viability and retained T cells responsive to stimulation throughout ex vivo culture. Multiplex immunofluorescence and immunohistochemistry showed key components of the tumor microenvironment, including relative proportions of CD4+ and CD8+ immune cell populations, were preserved. Specimens positive for PD-L1 or dMMR/MSI-high were enriched for cytokine upregulation, including T-cell response cytokines IFNγ and CXCL10, after αPD-1 treatment. To demonstrate clinical applicability of the sequential treatment strategy, CNBs from patients with lung, gastrointestinal or kidney cancer were profiled and differential cytokine induction in response to ICI treatment was observed. Conclusions The novel ex vivo platform presented is capable of detecting T-cell response to ICI treatment by using a sequential treatment strategy. This approach addresses challenges associated with cross-well heterogeneity in tissue composition and requires half as much tissue as a cross-well comparison, mitigating tissue limitations typically associated with non-surgical biopsies. Importantly, the platform is compatible with established functional assays as well as non-destructive spatial imaging, enabling researchers to characterize response to ICI longitudinally. Ongoing trials will enable clinicians to assess platform performance in predicting response to immunotherapy.
Year:
2025
The genetic reprogramming of T cells with chimeric antigen receptors (CAR) specifically targeting CD19 in B-cell malignancies or B-cell maturation antigen for plasma cell tumors has achieved remarkable success. CAR T-cell therapy represents a revolutionary strategy in personalized cancer care, leveraging the immune system's precision to target cancer cells with unprecedented efficacy. However, challenges persist, with resistance and relapse occurring in hematologic malignancies. Understanding the intricate mechanisms governing response and resistance is crucial, emphasizing factors such as pharmacokinetics, product attributes, and tumor biology. This review focuses on biomarkers associated with CAR T-cell therapy in mature B-cell non-Hodgkin lymphoma malignancies, underscoring the importance of preexisting tumor immune contexture. Previous findings highlight strong correlation between early peak levels of CAR-T cells after treatment initiation and treatment response. Maintaining an optimal CAR T-cell–to–tumor burden ratio is essential for sustained responses. Systemic and tumor immune contexture affects therapy outcomes, revealing preexisting immunity's role in CAR T-cell efficacy. The mechanistic impact of CAR-T cells was investigated using pre- and posttreatment biopsies, revealing specific markers associated with treatment response in refractory large B-cell lymphoma, across patients receiving CAR T-cell therapy in the second- and third-line settings, supporting precision medicine in developing next-generation cell therapies for hematologic malignancies. The evolution of the tumor microenvironment with therapy lines was also demonstrated, supporting earlier intervention with CAR T-cell therapy. Ongoing translational efforts, including single-cell omics analysis, aim to uncover additional factors that affect outcomes to develop more potent treatments.
Year:
2025
PURPOSE Immunoscore (IS) and circulating tumor DNA (ctDNA) are two emerging technologies in improving prognostication and tailoring adjuvant treatments in patients resected from a stage III colon cancer (CC). Here, we analyzed the prognostic value of the two biomarkers in patients who participated in the randomized phase III IDEA-France and HORG trials. METHODS Plasma samples were collected after surgery and before adjuvant chemotherapy. ctDNA analysis was performed using a clinically validated, personalized, tumor-informed 16-plex protein chain reaction assay. Multivariable analyses for time to recurrence (TTR; patients without recurrence or death due to CC) and overall survival (OS) were performed using ctDNA and IS results, along with other parameters including treatment duration and disease risk group. RESULTS Of the 554 patients with available ctDNA results, 445 were ctDNA-negative (80.3%) and 109 were ctDNA-positive (19.7%); baseline characteristics showed more T4/N2 and venous embolism/lymphatic invasion/perineural invasion+ in ctDNA-positive patients. With a median follow-up of 6.7 years, the 2-year TTR rate was 43.5% (95% CI, 34.1 to 52.6) for ctDNA-positive patients and 88.1% (95% CI, 84.7 to 90.8) for ctDNA-negative patients ( P < .0001). ctDNA was confirmed as an independent prognostic marker for both TTR (adjusted hazard ratio [adjHR], 5.21 [95% CI, 3.59 to 7.58]; P < .001) and OS (adjHR, 4.84 [95% CI, 3.40 to 6.89]; P < .001). ctDNA remained the most significant prognostic factor irrespective of disease stage, treatment duration, and IS results. IS was not prognostic in ctDNA-positive patients but remained a significant prognostic tool for ctDNA-negative patients. CONCLUSION In this combined analysis of two adjuvant trials dedicated to patients with stage III CC after surgery, ctDNA was detectable in 19.7% of the patients and was confirmed as a major independent prognostic biomarker. IS seems to bring additional prognostic information in the 80.3% of patients who are ctDNA-negative.
Year:
2025
Purpose: AtezoTRIBE phase II randomized study demonstrated that adding atezolizumab to first-line FOLFOXIRI (5-fluorouracil, oxaliplatin, irinotecan) plus bevacizumab prolongs progression-free survival (PFS) of patients with metastatic colorectal cancer (mCRC), with a modest benefit among proficient mismatch repair (pMMR). DetermaIO is an immune-related 27-gene expression signature able to predict benefit from immune checkpoint inhibition in triple-negative breast cancer. In this analysis of AtezoTRIBE, we investigated the predictive impact of DetermaIO in mCRC. Experimental Design: Patients with mCRC unselected for MMR status were randomly assigned (1:2) to FOLFOXIRI plus bevacizumab (control arm) or the same regimen with atezolizumab (atezolizumab arm). qRT-PCR by DetermaIO was performed on RNA purified from pretreatment tumors of 132 (61%) of 218 enrolled patients. A binary result (IO pos vs. IO neg ) adopting the preestablished DetermaIO cut-off point (0.09) was obtained, and an exploratory optimized cut-off point (IO OPT ) was computed in the overall population and in pMMR subgroup (IO OPTpos vs. IO OPTneg ). Results: DetermaIO was successfully determined in 122 (92%) cases, and 23 (27%) tumors were IO pos . IO pos tumors achieved higher PFS benefit from atezolizumab arm than IO neg (HR: 0.39 vs. 0.83; P interaction = 0.066). In pMMR tumors ( N = 110), a similar trend was observed (HR: 0.47 vs. 0.93; P interaction = 0.139). In the overall population, with the computed IO OPT cut-off point (0.277), 16 (13%) tumors were IO OPTpos and they derived higher PFS benefit from atezolizumab than IO OPTneg (HR: 0.10 vs. 0.85, P interaction = 0.004). Similar results were found in the pMMR subgroup. Conclusions: DetermaIO may be useful to predict benefit of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in mCRC. The exploratory IO OPT cut-off point should be validated in independent mCRC cohorts.
Year:
2025
Background: AtezoTRIBE phase II randomized study demonstrated that adding atezolizumab to first-line FOLFOXIRI (5fluoruracil, oxaliplatin, irinotecan) plus bevacizumab prolongs progression-free survival (PFS) of metastatic colorectal cancer (mCRC) patients, with a modest benefit among proficient mismatch repair (pMMR). DetermaIO is an immune-related 27-gene expression signature able to predict benefit from immune-checkpoint inhibition in triple-negative breast cancer. In this analysis of AtezoTRIBE, we investigated the predictive impact of DetermaIO in mCRC. Methods: mCRC patients unselected for MMR status were randomized(1:2) to FOLFOXIRI plus bevacizumab (control arm) or the same regimen with atezolizumab (atezolizumab arm). RT-qPCR by DetermaIO was performed on RNA purified from pre-treatment tumours of 132(61%) out of 218 enrolled patients. A binary result (IOpos versus IOneg) adopting the pre-established DetermaIO cut-point (0.09) was obtained, and an exploratory optimized cut-point (IOOPT) was computed in the overall population and in pMMR subgroup (IOOPTpos versus IOOPTneg). Results: DetermaIO was successfully determined in 122 (92%) cases, and 23 (27%) tumours were IOpos. IOpos tumours achieved higher PFS benefit from atezolizumab arm than IOneg (HR:0.39 versus 0.83, P interaction=0.066). In pMMR tumours (N=110), a similar trend was observed (HR:0.47 versus 0.93, P interaction=0.139). In the overall population, with the computed IOOPT cut-point (0.277), 16 (13%) tumours were IOOPTpos and they derived higher PFS benefit from atezolizumab than IOOPTneg(HR:0.10 versus 0.85, P interaction=0.004). Similar results were found in the pMMR subgroup. Conclusions :DetermaIO may be useful to predict benefit of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in mCRC. The exploratory IOOPT cut-point should be validated in independent mCRC cohorts.
Year:
2024
Kaplan Meier estimates of progression-free survival in the pMMR population (optimized cut-point), according to IO status (a) and to both IO status and treatment arm (b). Legend: HR: hazard ratio, NR: not reached. Control arm indicates FOLFOXIRI plus bevacizumab. Atezo arm indicates FOLFOXIRI plus bevacizumab and atezolizumab.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (17)
David Braun
Assistant Professor, Principal Investigator
Yale University Yale Cancer Center
Thierry André
Sorbonne Université
Filippo Pietrantonio
Researcher (non-academic)
Fondazione IRCCS Istituto Nazionale dei Tumori
Christian Capitini
Professor
University of Wisconsin-Madison
Joshua Routh
Assistant Clinical Professor
Arizona State University
Nima Kokabi
Emory University School of Medicine
Jean-François Emile
Université de Versailles Saint-Quentin-en-Yvelines
Federica Morano
Fondazione IRCCS Istituto Nazionale dei Tumori
Giampaolo Tortora
Professore Ordinario di Oncologia Medica
Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia
julien taieb
Professor Head of the department
Université Paris-Saclay
Sara Lonardi
Head of Dept
Istituto Oncologico Veneto
Minetta Liu
Research Collaborator, Professor
Mayo Clinic
Andrew K. Godwin
University of Kansas Medical Center
E. Martinelli
-
Pierre Laurent-Puig
Université Paris Descartes
Chiara Cremolini
University Hospital of Pisa
Kevin Eliceiri
University of Wisconsin-Madison
Make your next move.
Prepare your application
Review drafts before you send them.